XmAb942 (Xtend™ TL1A)
Novel high-potency anti-TL1A antibody designed for extended half-life, in Phase 1 development for the treatment of patients with IBD
XmAb942 is a monospecific anti-TL1A antibody, utilizing Xencor’s Xtend™ Fc Domain and proprietary Fc silencing technology, with potentially class-leading potency, and is under development for patients with inflammatory bowel diseases (IBD). The two most common forms of IBD are Crohn’s disease and ulcerative colitis.
Preclinical characterization was presented at the United Europe Gastroenterology Week (UEGW) October 2024. Half-life was 23 days, potentially supporting an 8- to 12-week dosing regimen in humans.
Xencor initiated dosing in a first-in-human, single-ascending dose study of XmAb942 in healthy volunteers in the fourth quarter of 2024 and expects initial data during the first half of 2025. (Press Release, November 4, 2024)